期刊文献+

术前强化阿托伐他汀治疗预防对比剂肾病的研究 被引量:7

Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography
下载PDF
导出
摘要 目的研究术前强化阿托伐他汀治疗在预防对比剂肾病中的作用。方法选取2010年8月至2011年2月期间我院60例行冠状动脉介入诊断与治疗的患者随机分为强化治疗组(A组)和常规剂量组(B组),每组患者各30例。全部采用标准水化治疗[0.9%NaCl溶液1ml/(kg·h)静脉水化12h,并鼓励患者多饮水]和给予阿托伐他汀10mg/d的基础上,强化治疗组术前24~72h予阿托伐他汀40mg口服.观察术前和术后1、3、7d血清肌酐(Scr)、内生肌酐清除率(Ccr)、血β2-微球蛋白(β2-Mg)、胱抑素C、高敏C反应蛋白(hs-CRP)的改变情况、记录术中造影剂的用量以及有无不良反应的发生。结果术后第1、3天,两组Ccr与术前相比明显下降,血肌酐、β2-微球蛋白、胱抑素C、hs-CRP分别与术前比较明显升高(P<0.05),组间比较,A组Ccr较B组高,差异有统计学意义,血肌酐、β2-Mg、胱抑素C、hs-CRP明显低于B组(P<0.05)。术后第7天,A、B两组肌酐、Ccr、血β2-微球蛋白、胱抑素C、hs-CRP与术前相比无差异。A组对比剂肾病发生率为0,B组出现1例,占3.33%。结论对比剂可能造成轻微一过性肾损害,术前强化阿托伐他汀治疗可能预防对比剂肾病,机制可能与抑制炎症反应有关,值得术前推广。 Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy(CIN) in patients underwent coronary angiography.Methods From August 2010 to February 2011,60 patients underwent coronary angiography were randomized to the intensive therapy group(A group) and low dose group(B group).All patients received atorvastatin 10 mg/day on the basis of hydrated therapy(0.9% NaCl solution 1 ml /(kg·h) intravenous hydration 12 h,and encourage patients to drink more water),and high dose group received additional atorvastatin 80 mg at 24 to 72hours before procedure.Serum creatinine(Scr),endogenous creatinine clearance rate(Ccr),serum β2-microglobulin,cystatin c,Hs-CRP before and after the procedure were compared between the two groups.The amount of contrast agent in patients and incidence of adverse reactions were recorded.Results Baseline demographic characteristics and nephropathy risk factors were similar between the two groups.After day 1 and day 3,two groups of serum creatinine(Scr),serum β2-microglobulin(β2-M),cystatin c,Hs-CRP significantly increased when compared with those of preoperation(P〈0.05),and those in A group were lower than those in B group(P〈0.05).3 days after surgery,serum creatinine(Scr),serum β2-microglobulin(β2-M),cystatin c,Hs-CRP in two groups,significantly increased when compared the postoperative day 1,the difference was statistically significance(P〈0.05).Postoperative day 7,serum creatinine(Scr),endogenous creatinine clearance rate(Ccr),serum β2-microglobulin(β2-M),cystatin c,HS-CRP in two groups had no significant difference when compared with those of preoperation.Conclusion High dose atorvastatin use before angiography is superior to low dose atorvastatin on attenuating contrast induced renal dysfunction.High dose atorvastatin use before angiography is worth promoting.
出处 《海南医学》 CAS 2011年第10期44-46,共3页 Hainan Medical Journal
关键词 阿托伐他汀 对比剂肾病 血清肌酐(Scr) 内生肌酐清除率(Ccr) 血Β2-微球蛋白 Atorvastatin Contrast induced nephropathy Endogenous creatinine clearance rate Serum β2-microglobulin
  • 相关文献

参考文献9

  • 1Liistro F, Falsini G, Bologness L. The clinical burden of contrast media-induced nephropathy [J]. Hal Heart J, 2003, 4: 668.
  • 2赵亮,李虹.两种水化疗法对预防对比剂肾病的效果研究[J].医学与哲学(B),2010,31(2):28-29. 被引量:13
  • 3王玲,倪兆慧,何奔.对比剂肾病研究进展[J].介入放射学杂志,2007,16(1):66-69. 被引量:12
  • 4李玉兰,周旭晨,黄榕翀.行PCI术的老年患者发生对比剂肾病危险因素分析[J].中国现代医药杂志,2009,11(8):40-42. 被引量:4
  • 5Norman EL, Vandana SM. Radiocontrast nephropathy [J]. Curr Interv Card Rep, 2000, 2: 335.
  • 6Bonnet J, McPhemon R, Tedgui A, et al. Comparative effects of 10 mg versus 80 nag Atorvastatin on high sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study [J]. Clin Ther, 2008, 30: 2298-2313.
  • 7Yildiz A, Cakar A, Baskurt M, et al. The effects of atorvastatin thera- py on endothelial function in patients with coronary artery disease [J]. Cardiovascular Ultrasound, 2007, 30(5): 51.
  • 8Ge CJ, Lu SZ, Chen YD, et al. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-re- active protein in hypertensive patients with primary hypercholesterolemia [J]. Heart Vcssels, 2008, 23(2): 91.
  • 9Asher J, Houston M. Statins and C-reactive protein levels [J]. Clin Hypertens (Greenwieh), 2007, 9(8): 622.

二级参考文献45

  • 1徐红,陈丽萌,李学旺.肾功能不全患者发生造影剂肾病的危险因素和预后[J].中国医学科学院学报,2005,27(2):232-236. 被引量:29
  • 2李美花,范利.老年人造影剂肾病及临床相关因素分析[J].中国老年学杂志,2005,25(6):649-651. 被引量:23
  • 3Bartholomew BA, Harjai KJ, Dukkipati S, et al.Impact of nephropathy after percutaneous coronary intervention and a method for risk statification.Am J Cardiol,2004,93:1515-1519.
  • 4Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol,2002,90:1068- 1073.
  • 5Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol,2003,15:18 -22.
  • 6Nikolsky E, Mehran R, Lasic Z, et al. Low hematoerit predicts contrast-indueed nephropathy after percutaneous coronary interventions. [J] Kidney Int,2005,67:706-713.
  • 7Nikolsky E, Aymong ED, et al. Radiocontrast nephropathy: identifying the highrisk patient and the implications of exacerbating renal function. [J]. Rev Cardiovasc Med,2003,4(Suppl 1):S7-S14.
  • 8Hall KA, Wong RW, et al. Contrastinduced nephrotoxicity: the effects of vasodilator therapy[J].Surg Res,1992,53:317-320.
  • 9Lasser EC, Lyon SG. Reports on contrast media reactions: analysis of data from reports to the US Food and Drug Administration [J]. Radiology, 1997,203:605-610.
  • 10Gussenhoven M J, Ravensbergen J, van Boekel JH, et al. Renal dysfunction after angiography;a risk factor analysis in patients with peripheralvaseular disease. J Cardiovasc Surg,1991,32:81-86.

共引文献26

同被引文献80

  • 1汪斌,刘志忠,张丰富.冠状动脉介入诊治中高敏C反应蛋白与造影剂肾病的相关性分析[J].中国医药,2007,2(8):457-459. 被引量:35
  • 2Liistro F, Falsini G,Bolognese L.The clinical burden of contrast media-induced nephropathy[J].Ital Heart J,2003,4(10):668.
  • 3Goldenberg S,Matetzky.Nephropathy induced by contrast media:pathogenesis,risk factors and preventive strategies[J].Can Med Assoc,2005,172(11):1461.
  • 4I Tumlin J,Stacul F, Adam A,et al.Pathophysiology of contrastinduced nephropathy[J].Am J Cardio,2006,98(6A): 14.
  • 5Patti G,Nusca A,Chello M,et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention[J]. AmJ Cardiol,2008,101 (3):279.
  • 6Jo SH,Koo BK,Park JS,et al.Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography(PROMISS) trial-arandomized controlled study[J].Am Heart J,2008,155(3):499.
  • 7Ichiki T, Takeda K,Tokunou T, et al.Downregulation of angiotensin 1I type 1 receptor by hydrophobic 3-hydroxy-3methylglutary 1 coenzyme A reductase inhibitors in vascular smooth muscle cells[J]. Arterioscler Thromb Vasc Biol,2001,21 (12): 1896.
  • 8Dulak J,Loboda A,Jazwa A,et al.Atorvastatin affects several angiogenic mediators in human endothelial cells[J]. Endothelium,2005,12(2):233.
  • 9Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin 1I type 1 receptor by hydrophobic 3-hydroxy-3methylglutary 1 coenzyme A reductase inhibitors in vascular smooth muscle cells [ J ]. Artefioscler Thromb Vasc Biol,2001,21 (12) : 1896.
  • 10Dulak J, Loboda A, Jazwa A, et al. Atorvastatin affects several angi0genic mediators in human endothelial cells [ J ]. Endothelium, 2005,12 ( 2 ) : 233.

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部